The antiplatelet effect of aspirin is reduced by proton pump inhibitors in patients with coronary artery disease

Heart

Volumn 96, Issue 5, 2010, Pages 368-371

  Würtz, Morten ^a   Grove, Erik L ^a   Kristensen, Steen D ^a   Hvas, Anne Mette ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONIC ACID; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PADGEM PROTEIN; PANTOPRAZOLE; PROTON PUMP INHIBITOR; THROMBOXANE B2;

ADJUVANT THERAPY; AGE DISTRIBUTION; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; FAMILY HISTORY; FEMALE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIORITY JOURNAL; SEX RATIO; SMOKING; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

AGED; ASPIRIN; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; P-SELECTIN; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; REGISTRIES; THROMBOXANE B2;

EID: 77649210337     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/hrt.2009.181107     Document Type: Article

References (35)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
2. Grove EL, Kristensen SD. Update on oral antiplatelet therapy: principles, problems and promises. Future Cardiol 2009;5:247-58.
3. Krasopoulos G, Brister SJ, Beattie WS, et al. Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis. BMJ 2008;336:195-8.
4. Snoep JD, Hovens MM, Eikenboom JC, et al. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med 2007;167:1593-9.
5. Yeomans ND, Tulassay Z, Juhasz L, et al. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. Acid suppression trial: ranitidine versus omeprazole for NSAID-associated ulcer treatment (ASTRONAUT) study group. N Engl J Med 1998;338:719-26.
6. Shore PA, Brodie BB, Hogben CA. The gastric secretion of drugs: a pH partition hypothesis. J Pharmacol Exp Ther 1957;119:361-9.
7. Oosterhuis B, Jonkman JH. Omeprazole: pharmacology, pharmacokinetics and interactions. Digestion 1989;44(Suppl 1):9-17.
8. Giraud MN, Sanduja SK, Felder TB, et al. Effect of omeprazole on the bioavailability of unmodified and phospholipid-complexed aspirin in rats. Aliment Pharmacol Ther 1997;11:899-906.
9. Hollander D, Dadufalza VD, Fairchild PA. Intestinal absorption of aspirin. Influence of pH, taurocholate, ascorbate, and ethanol. J Lab Clin Med 1981;98:591-8.
10. Fernandez-Fernandez FJ. Might proton pump inhibitors prevent the antiplatelet effects of low- or very low-dose aspirin? Arch Intern Med 2002;162:2248.
11. Lichtenberger LM, Ulloa C, Romero JJ, et al. Nonsteroidal anti-inflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats. Gastroenterology 1996;111:990-5.
12. Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008;51:256-60.
13. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-8.
14. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:699-700.
15. Cleanthis M, Smout J, Bhattacharya V, et al. Soluble but not platelet P-selectin correlates with spontaneous platelet aggregation: a pilot study. Clin Appl Thromb Hemost 2008;14:227-33.
16. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006;367:606-17.
17. Hedegaard SS, Hvas AM, Grove EL, et al. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration. Thromb Res 2009;124:96-100.
18. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J 2007;28:1673-5.
19. Maeng M, Okkels JL, Rasmussen K, et al. Target lesion revascularisation in patients treated with a sirolimus-eluting or paclitaxel-eluting stent. Heart 2007;93:694-7.
20. Toth O, Calatzis A, Penz S, et al. Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood. Thromb Haemost 2006;96:781-8.
21. Patrono C, Ciabattoni G, Pinca E, et al. Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980;17:317-27.
22. Patrono C, Rocca B. Drug insight: aspirin resistanceefact or fashion? Nat Clin Pract Cardiovasc Med 2007;4:42-50.
23. Anand BS, Sanduja SK, Lichtenberger LM. Effect of omeprazole on the bioavailability of aspirin: a randomized controlled study on healthy subjects [abstract]. Gastroenterology 1999;116:A371.
24. Inarrea P, Esteva F, Cornudella R, et al. Omeprazole does not interfere with the antiplatelet effect of low-dose aspirin in man. Scand J Gastroenterol 2000;35:242-6.
25. Adamopoulos AB, Sakizlis GN, Nasothimiou EG, et al. Do proton pump inhibitors attenuate the effect of aspirin on platelet aggregation? A randomized crossover study. J Cardiovasc Pharmacol 2009;54:163- 8.
26. Patrono C, Bachmann F, Baigent C, et al. Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. Eur Heart J 2004;25:166-81.
27. Siller-Matula JM, Spiel AO, Lang IM, et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148-5.
28. Clark K, Lam LT, Gibson S, et al. The effect of ranitidine versus proton pump inhibitors on gastric secretions: a meta-analysis of randomised control trials. Anaesthesia 2009;64:652-7.
29. Stedman CA, Barclay ML. Review article: comparison of the pharmacokinetics, acid suppression and efficacy of proton pump inhibitors. Aliment Pharmacol Ther 2000;14:963-78.
30. Naritomi Y, Terashita S, Kagayama A. Identification and relative contributions of human cytochrome P450 isoforms involved in the metabolism of glibenclamide and lansoprazole: evaluation of an approach based on the in vitro substrate disappearance rate. Xenobiotica 2004;34:415-27.
31. Dupont I, Berthou F, Bodenez P, et al. Involvement of cytochromes P-450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab Dispos 1999;27:322-6.
32. Wallen NH, Ladjevardi M, Albert J, et al. Influence of different anticoagulants on platelet aggregation in whole blood; a comparison between citrate, low molecular mass heparin and hirudin. Thromb Res 1997;87:151-7.
33. Kalb ML, Potura L, Scharbert G, et al. The effect of ex vivo anticoagulants on whole blood platelet aggregation. Platelets 2009;20:7-11.
34. Schwartz KA, Schwartz DE, Barber K, et al. Non-compliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med 2008;6:46.
35. Pedersen SB, Grove EL, Nielsen HL, et al. Evaluation of aspirin response by Multiplate (R) whole blood aggregometry and light transmission aggregometry. Platelets 2009;20(6):415-20.